HAP Trading’s PTC Therapeutics PTCT Stock Holding History

HAP Trading’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-101,707	Closed	-$1M	–	1128
2017 Q1	$1M	Buy	+101,707	New	+$1.23M	0.06%	232

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

HAP Trading's PTCT Position: Q2 2017 in Review

HAP Trading sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 101,707 shares — an estimated $1M sold.

HAP Trading first reported a position in PTCT in Q1 2017 and held it in 1 quarter. The position peaked at $1M in Q1 2017. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

HAP Trading reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
HAP Trading sold 101,707 PTC Therapeutics shares in Q2 2017, an estimated $1M.
HAP Trading first reported a position in PTC Therapeutics in Q1 2017 and held it in 1 quarter.
HAP Trading's PTC Therapeutics position peaked at $1M in Q1 2017.
114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on HAP Trading's 13F filing for Q2 2017, filed 10 Aug 2017.